---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-005105"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:11:30.261423+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma closes $4.2M Reg A offering of 1.49M units at $2.80/unit

## Summary
- Gross proceeds $4,172,000 from 1,490,000 units (one share + one warrant) priced at $2.80/unit; closed March 10, 2025.
- Warrants exercisable at $2.80/share for 5 years from issuance; not listed on any exchange.
- Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin microarray needle patch.
- Maxim Group LLC lead placement agent; customary 7.5% cash fee plus expense reimbursement.
- Offering qualified under Tier II Regulation A on March 6, 2025; subscription agreement with a single investor.

## SEC filing metadata
- accession: 0001062993-25-005105
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325005105/0001062993-25-005105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325005105/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-005105
- JSON: https://secwatch.observer/filing/0001062993-25-005105.json
- Plain text: https://secwatch.observer/filing/0001062993-25-005105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.